Tempus AI, Inc. (NASDAQ:TEM) Receives $69.33 Average Target Price from Brokerages

Tempus AI, Inc. (NASDAQ:TEM) has earned an average recommendation of “Hold” from the twenty-one research firms that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and eleven have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $69.3333.

Several equities analysts have recently weighed in on TEM shares. TD Cowen reiterated a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. Guggenheim boosted their target price on shares of Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Roth Capital began coverage on shares of Tempus AI in a report on Tuesday, September 8th. They set a “neutral” rating and a $67.00 target price for the company. Freedom Capital upgraded shares of Tempus AI to a “hold” rating in a research report on Tuesday, June 30th. Finally, Rothschild & Co Redburn initiated coverage on shares of Tempus AI in a research note on Tuesday, September 8th. They set a “neutral” rating and a $67.00 price target on the stock.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: CEO commentary outlining Tempus AI’s growth strategy and projected Medicare revenue has strengthened confidence that reimbursement expansion could provide a significant new revenue stream. Tempus AI Stock Roars Back 92% From July Low After CEO Lays Out Growth Plan
• Positive Sentiment: Morgan Stanley’s updated outlook reportedly incorporated additional reimbursement-driven revenue potential, helping fuel a sharp weekly advance in TEM shares and reinforcing the bullish growth narrative. Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook
• Positive Sentiment: Trading momentum remains strong: shares have rebounded roughly 92% to 95% from the July low, with market capitalization moving above $14 billion. Above-average volume and elevated call-option activity indicate substantial speculative interest. Tempus AI Stock Is Soaring
• Neutral Sentiment: Analysts and market commentators are assessing whether the recent surge can continue. The rally has improved sentiment, but the sharp move also raises the risk of profit-taking and increased volatility. Strength Seen in Tempus
• Negative Sentiment: Zacks cautioned that recent earnings-estimate revision trends may not support another near-term advance, while brokerages maintain an average “Hold” rating. Tempus also remains unprofitable, making the stock particularly sensitive to valuation concerns and changes in growth expectations. Tempus AI Receives Average Hold Rating

Tempus AI Stock Performance

TEM stock opened at $77.84 on Thursday. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. Tempus AI has a 1 year low of $40.77 and a 1 year high of $104.32. The company has a market cap of $14.04 billion, a P/E ratio of -54.06 and a beta of 3.72. The stock’s fifty day moving average price is $57.19 and its 200-day moving average price is $52.90.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The company had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.Tempus AI’s revenue was up 21.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.22) earnings per share. On average, equities analysts forecast that Tempus AI will post -1.38 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Eric Lefkofsky sold 250,000 shares of Tempus AI stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $42.06, for a total transaction of $10,515,000.00. Following the transaction, the chief executive officer directly owned 200,000 shares in the company, valued at approximately $8,412,000. The trade was a 55.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James Rogers sold 26,313 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $60.00, for a total value of $1,578,780.00. Following the sale, the chief financial officer directly owned 106,024 shares of the company’s stock, valued at $6,361,440. This represents a 19.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 1,254,701 shares of company stock valued at $73,877,392. 24.26% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TEM. EMC Capital Management purchased a new stake in Tempus AI in the 2nd quarter worth approximately $29,000. Whittier Trust Co. lifted its holdings in Tempus AI by 190.0% during the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after purchasing an additional 570 shares in the last quarter. CoreCap Advisors LLC lifted its holdings in Tempus AI by 293.4% during the second quarter. CoreCap Advisors LLC now owns 1,019 shares of the company’s stock valued at $59,000 after purchasing an additional 760 shares in the last quarter. Global Assets Advisory LLC purchased a new position in Tempus AI during the first quarter valued at approximately $46,000. Finally, Eurizon Capital SGR S.p.A. bought a new position in shares of Tempus AI in the fourth quarter worth approximately $70,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.